Drugs / HCP1904-3
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05407220 | Jun → Jul 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05199129 | Nov 2021 → Sep 2022 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1904-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199129 ↗ |
| Route | Oral | “Take once daily for 8 weeks orally” NCT05199129 ↗ |